Table 2.
Laboratory, US parameters, and therapy of selected population
| Variables | Controlled (C) | Uncontrolled (UC) | p value | ||
|---|---|---|---|---|---|
| % | % | ||||
| T-CHOL (mg/dl) | 195.05 ± 6.03 | 195.30 ± 7.63 | NS | ||
| HDL low | 3 | 7.69 | 13 | 32.50 | 0.001 |
| LDL (mg/dl) | 111.50 ± 5.95 | 115.59 ± 6.96 | NS | ||
| Triglycerides (mg/dl) | 138.28 ± 9.51 | 146.60 ± 11.46 | NS | ||
| Glycemia (mg/dl) | 105.54 ± 5.42 | 105.80 ± 4.02 | NS | ||
| LVH | 18 | 46.15 | 16 | 40 | NS |
| LVMI (g/m2) | 118.93 ± 7.28 | 120.51 ± 11.42 | NS | ||
| Carotid plaques | 16 | 41.03 | 16 | 40.00 | NS |
| Carotid IMT max (mm) | 1.78 ± 0.16 | 1.87 ± 0.19 | NS | ||
| E/A | 0.93 ± 0.06 | 0.84 ± 0.04 | NS | ||
| Combination therapy | 15 | 38.46 | 25 | 62.50 | 0.002 |
| Diuretics | 16 | 41.03 | 26 | 65.00 | 0.002 |
| β-blockers | 23 | 58.97 | 22 | 55.00 | NS |
| RAS inhibitors | 32 | 82.05 | 40 | 100.00 | NS |
| Dihydropyridine calcio-antagonists | 13 | 33.33 | 21 | 52.50 | 0.018 |
Data are presented as means ± SEM, unless otherwise indicated
T-CHOL total cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein, LVH left ventricular hypertrophy, LVMI left ventricular mass index, IMT intima–media thickness, combination therapy use of at least two antihypertensive drugs, RAS renin–angiotensin system; NS not significant.